As of 2025-03-19, the EV/EBITDA ratio of AnaptysBio Inc (ANAB) is -2.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AnaptysBio's latest enterprise value is 371.93 mil USD. AnaptysBio's TTM EBITDA according to its financial statements is -164.42 mil USD. Dividing these 2 quantities gives us the above AnaptysBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 12.8x | 10.2x |
| Forward P/E multiples | 9.4x - 14.1x | 11.4x |
| Fair Price | (46.38) - (64.39) | (54.02) |
| Upside | -387.4% - -499.0% | -434.7% |
| Date | EV/EBITDA |
| 2025-03-14 | -2.44 |
| 2025-03-13 | -2.39 |
| 2025-03-12 | -2.56 |
| 2025-03-11 | -2.52 |
| 2025-03-10 | -2.37 |
| 2025-03-07 | -2.30 |
| 2025-03-06 | -2.31 |
| 2025-03-05 | -2.38 |
| 2025-03-04 | -2.10 |
| 2025-03-03 | -1.98 |
| 2025-02-28 | -2.39 |
| 2025-02-27 | -2.31 |
| 2025-02-26 | -2.42 |
| 2025-02-25 | -2.46 |
| 2025-02-24 | -2.46 |
| 2025-02-21 | -2.72 |
| 2025-02-20 | -2.77 |
| 2025-02-19 | -2.91 |
| 2025-02-18 | -2.94 |
| 2025-02-14 | -3.21 |
| 2025-02-13 | -2.85 |
| 2025-02-12 | -2.26 |
| 2025-02-11 | -1.56 |
| 2025-02-10 | -1.68 |
| 2025-02-07 | -1.97 |
| 2025-02-06 | -2.25 |
| 2025-02-05 | -2.25 |
| 2025-02-04 | -2.33 |
| 2025-02-03 | -2.36 |
| 2025-01-31 | -2.60 |
| 2025-01-30 | -2.50 |
| 2025-01-29 | -2.50 |
| 2025-01-28 | -2.62 |
| 2025-01-27 | -2.51 |
| 2025-01-24 | -2.39 |
| 2025-01-23 | -2.35 |
| 2025-01-22 | -2.27 |
| 2025-01-21 | -2.40 |
| 2025-01-17 | -2.21 |
| 2025-01-16 | -2.06 |
| 2025-01-15 | -2.14 |
| 2025-01-14 | -2.03 |
| 2025-01-13 | -1.98 |
| 2025-01-10 | -1.90 |
| 2025-01-08 | -1.93 |
| 2025-01-07 | -2.02 |
| 2025-01-06 | -2.11 |
| 2025-01-03 | -1.97 |
| 2025-01-02 | -1.74 |
| 2024-12-31 | -1.72 |